ABOS (Acumen Pharmaceuticals) LT-Debt-to-Total-Asset: 0.13 (As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.30
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals LT-Debt-to-Total-Asset?

Acumen Pharmaceuticals ABOS -0.43% 34 LT-Debt-to-Total-Asset is 0.13 as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Acumen Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.13.

Acumen Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.14) to Mar. 2026 (0.13). It may suggest that Acumen Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Acumen Pharmaceuticals  (NAS:ABOS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Acumen Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Acumen Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals LT-Debt-to-Total-Asset Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.09 0.12 0.18

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.17 0.19 0.18 0.13
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Acumen Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=22.396/122.833
=

Acumen Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=16.924/133.629
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.13 mean?
Acumen Pharmaceuticals (ABOS) has a LT-Debt-to-Total-Asset of 0.13 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Acumen Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.13. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' LT-Debt-to-Total-Asset compare to QTTB and TNYA?
Acumen Pharmaceuticals' LT-Debt-to-Total-Asset of 0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current LT-Debt-to-Total-Asset of 0.13. The current LT-Debt-to-Total-Asset is 0.13. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current LT-Debt-to-Total-Asset is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price